Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
INTERMEDIATES AND PROCESS FOR THE SYNTHESIS OF 17-UNSUBSTITUTED 16.BETA.-ARYLOXY 4-AZASTEROIDS
Document Type and Number:
WIPO Patent Application WO/1999/032507
Kind Code:
A2
Abstract:
The novel process of this invention involves the stereoselective synthesis of certain 16-substituted 4-aza-5$g(a)-androst-1-en-3-ones, and the useful intermediates obtained therein.

Inventors:
HUMPHREY GUY R (US)
MILLER ROSS A (US)
LI WENJIE (US)
Application Number:
PCT/US1998/027136
Publication Date:
July 01, 1999
Filing Date:
December 18, 1998
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
MERCK & CO INC (US)
HUMPHREY GUY R (US)
MILLER ROSS A (US)
LI WENJIE (US)
International Classes:
C07C59/205; C07C69/00; C07C69/716; C07D221/18; C07D221/22; C07D239/02; C07D401/02; C07D473/00; (IPC1-7): C07J73/00; C07J1/00; C07C59/205
Domestic Patent References:
WO1995011254A11995-04-27
WO1997030069A11997-08-21
Foreign References:
US5696266A1997-12-09
EP0473225A21992-03-04
US5091534A1992-02-25
Other References:
KING A O ET AL: "Iodotrimethylsilane-mediated 2-monohalogenation of 4-aza-5.alpha.-androstan-3-one steroids" JOURNAL OF ORGANIC CHEMISTRY., vol. 58, no. 12, 4 June 1993, pages 3384-3386, XP002095967 EASTON US
Attorney, Agent or Firm:
MERCK & CO., INC. (NJ, US)
MERCK & CO., INC. (NJ, US)
Download PDF:
Claims:
WHAT IS CLAIMED:
1. A process for producing a compound of structural formula (11): wherein: Ar is an unsubstituted or monoor disubstituted phenyl, naphthyl, or 5,6 or 7 membered heteroaromatic ring containing at least one member selected from the group consisting oufonze ring oxygen atom, one ring sulfur atom, 14 ring nitrogen atoms, or combinations thereof; in which the heteroaromatic ring can also be fused with one benzo or heteroaromatic ring; producedby: treating a compound of structural formula (10): with potassium tbutoxide, and isolating the resulting product (11).
2. The process of Claim 1 additionally comprising the step of producing a compound of structural formula (10): by treating a compound of structural formula (9): with trimethylsilyl chloride in the presence of an organic base and adding iodine, and isolating the resulting product (10).
3. The process of Claim 2 additionally comprising the step of producing a compound of structural formula (9): by treating a compound of structural formula (8): with potassium tbutoxide and adding ArF, and isolating the resulting product (9).
4. The process of Claim 3 additionally comprising the step of producing a compound of structural formula (8): by hydrogenating a compound of structural formula (7): and isolating the resulting product (8).
5. The process of Claim 4 additionally comprising the step of producing a compound of structural formula (7): by treating a compound of structural formula (6): with lithium trisecbutylborohydride, followed by an oxidative workup, and and isolating the resulting product (7).
6. The process according to Claim 5, additionally comprising the step of producing a compound of structural formula (6): by treating a compound of structural formula (5): with ammonium acetate in refluxing acetic acid, and isolating the resulting product (6).
7. The process according to Claim 6, additionally comprising the step of producing a compound of structural formula (5) by treating a compound of structural formula (4): with sodium periodate and catalytic potassium permanganate and sodium carbonate, and isolating the resulting product (5).
8. The process according to Claim 7, additionally comprising the step of producing a compound of structural formula (4): by treating a compound of structural formula (3): with 10% Pd/C, cyclohexene, and ethanol in an organic solvent, and isolating the resulting product (4).
9. The process according to Claim 8, additionally comprising the step of producing a compound of structural formula (3): by treating a compound of structural formula (2): with aluminum isopropoxide and 2butanone in the presence of organic base in an organic solvent, followed by addition of aqueous acid to the solution, neutralization with aqueous base and isolation of (3) as a solution in the organic solvent.
10. The process according to Claim 9, additionally comprising the step of producing a compound of structural formula (2): by treating a compound of structural formula (1): with methyl magnesium chloride in the presence of cerium chloride in an organic solvent.
11. The process according to Claim 1 wherein Ar is selected from: unsubstituted or monoor disubstituted phenyl, naphthyl, pyridyl, furyl, pyrrolyl, thienyl, isothiazolyl, imidazolyl, benzimidazolyl, tetrazolyl, pyrazinyl, pyrimidyl, quinolyl, isoquinolyl, benzofuryl, isobenzofuryl, benzothienyl, pyrazolyl, indolyl, isoindolyl, purinyl, carbazolyl, isoxazolyl, thiazolyl, oxazolyl, benzthiazolyl, and benzoxazolyl.
12. The process according to Claim 11 additionally comprising the step of producing a compound of structural formula (10): by treating a compound of structural formula (9): with trimethylsilyl chloride in the presence of an organic base and adding iodine, and isolating the resulting product (10).
13. The process according to Claim 12 additionally comprising the step of producing a compound of structural formula (9): by treating a compound of structural formula (8): with potassium tbutoxide and adding ArF, and isolating the resulting product (9).
14. A process for producing a compound of structural formula (11): wherein: Ar is an unsubstituted or monoor disubstituted phenyl, naphthyl, or 5,6 or 7 membered heteroaromatic ring containing at least one member selected from the group consisting of : one ring oxygen atom, one ring sulfur atom, 14 ring nitrogen atoms, or combinations thereof; in which the heteroaromatic ring can also be fused with one benzo or heteroaromatic ring; comprising: (a) by treating a compound of structural formula (1): with methyl magnesium chloride in the presence of cerium chloride in an organic solvent to produce (2): (b) treating the compound of structural formula (2) with aluminum isopropoxide and 2butanone in the presence of organic base in an organic solvent, followed by addition of aqueous acid to the solution, neutralization with aqueous base and isolation (3) as a solution in the organic solvent: (c) treating the compound of structural formula (3) with 10% Pd/C, cyclohexene, and ethanol in an organic solvent, and isolating the resulting product (4): (d) treating the compound of structural formula (4) with sodium periodate and catalytic potassium permanganate and sodium carbonate, and isolating the resulting product (5): (e) treating the compound of structural formula (5) with ammonium acetate in refluxing acetic acid, and isolating the resulting product (6): (fl treating the compound of structural formula (6) with lithium trisecbutylborohydride, followed by an oxidative workup, and and isolating the resulting product (7): (g) hydrogenating the compound of structural formula (7) and isolating the resulting product (8): (h) treating the compound of structural formula (8) with potassium tbutoxide, adding ArF, and isolating the resulting product (9): (i) treating the compound of structural formula (9) with trimethylsilyl chloride in the presence of an organic base and adding iodine, and isolating the resulting product (10): (i) treating the compound of structural formula (10) with potassium tbutoxide, and isolating the resulting product (11).
15. The process of Claim 14 wherein Ar is 4 methylphenyl.
16. A compound selected from:.
Description:
TITLE OF THE INVENTION INTERMEDIATES AND PROCESS FOR THE SYNTHESES OF 17-UNSUBSTITUTED 16. BETA.-ARYLOXY 4-AZASTEROIDS

CROSS REFERENCE TO RELATED APPLICATIONS The present application claims priority of U. S. provisional application Serial No. 60/068,536, filed December 23,1997.

BACKGROUND OF THE INVENTION The principal mediator of androgenic activity in some target organs, e. g., the prostate, is 5a-dihydrotestosterone ("DHT"), formed locally in the target organ by the action of 5a-reductase, which converts testosterone to DHT. Certain undesirable physiological manifestations, such as acne vulgaris, seborrhea, female hirsutism, androgenic alopecia (also called androgenetic alopecia) which inclues female and male pattern baldness, and benign prostatic hyperplasia, are the result of hyperandrogenic stimulation caused by an excessive accumulation of testosterone ("T") or similar androgenic hormones in the metabolic system. Inhibitors of 5a-reductase will serve to prevent or lessen symptoms of hyperandrogenic stimulation in these organs. See especially United States Patent Nos. 4,377,584, issued March 22,1983, and 4,760,071, issued July 26,1988, both assigne to Merck & Co., Inc. It is now known that a second 5a-reductase isozyme exists, which interacts with skin tissues, especially in scalp tissues. See, e. g., G.

Harris, et al., Proc. Natl. Acad. Sci. USA, Vol. 89, pp. 10787-10791 (Nov.

1992). The isozyme that principally interacts in skin tissues is conventionally designated as 5a-reductase 1 (or 5a-reductase type 1), while the isozyme that principally interacts within the prostatic tissues is designated as 5a-reductase 2 (or 5a-reductase type 2).

U. S. 5,237,064 describes a process for producing 70- substituted 5a-androstan-3-ones. U. S. 5,470,976 describes the stereoselective hydrogenation of the delta-5 double bond of a 17- substituted azasteroid. U. S. 5,120,847 and U. S. 5,021,575 relate to the insertion of a double bond at the 1,2 position of a 4-azasteroid.

The instant invention provides an improved process for the synthesis of 16-substituted 7-ß-methyl-4-aza-5α-androst-1-en-3-ones. 16ß- substituted 7-ß-methyl-4-aza-5α-androst-1-en-3-ones are described in PCT publication WO 95/11254. Also provided by the present invention are intermediates useful in the present process.

SUMMARY OF THE INVENTION The novel process of this invention involves the stereoselective synthesis of certain 16-substituted 4-aza-5a-androst-1-en- 3-ones, and the useful intermediates obtained therein. These novel intermediates and this novel process can be exemplified in the following embodiment. , AI (O-iPr) 3 0 Toluene, Et3N l l l 0 (3) 10% Pd/C, 0-0 EtOH, Toluene, Dû O (4)

1. L-Selectride t -5° C, THF OH 2. H202, NAOS 0 N H (7) 1. KOtBu, NMP, » \ 4-fluorotoluene 7 's 1400C 0 m H H Me Me 0 S X 1. KOtBu, THF 0 l = DMF,-15°C 2. Water (11)

The products of the present process are useful as a inhibitors of 5a-reductase, particularly 5a-reductase type 1.5a- reductase inhibitors are useful in the treatment of hyperandrogenic disorders such as benign prostatic hyperplasia, acne vulgaris, seborrhea, female hirsutism, androgenic alopecia (androgenetic alopecia), including male pattern baldness, and the prevention and treatment of prostatic carcinoma.

DETAILED DESCRIPTION OF THE INVENTION A general procedure for the process of the present invention is shown below:

, AI (O-iPr) 3 O Toluene, Et3N l l | 0 (3) 10% Pd/C, 0 0 EtOH, Toluene, DBU O (4) 1. L-Selectride 4s -50 C, THF OH 2. H202, NaOH H (7) I Air O 0 1. KOtBu, THF 0 N z- DMF,-15°C 2. Water (11)

wherein Ar is: unsubstituted or mono-or di-substituted phenyl, naphthyl, or 5,6 or 7 membered heteroaromatic ring containing at least one member selected from the group consisting of one ring oxygen atom, one ring sulfur atom, 1-4 ring nitrogen atoms, or combinations thereof; in which the heteroaromatic ring can also be fused with one benzo or heteroaromatic ring.

When Ar is heteroaryl, the heteroaryl ring may be attache within structural formula I or substituted on any carbon atom in the ring which results in the creation of a stable structure.

The substituents on the aryl and heteroaryl groups named above are independently selected from: i) halo; hydroxy; cyano; nitro; mono-, di-or trihalomethyl; mono-, di-or trihalomethoxy; C2 6 alkenyl; C3-6 cycloalkyl; formyl; hydrosulfonyl; carboxy; ureido; ii) C1-6 alkyl; hydroxy C1-6 alkyl; C1-6 alkyloxy; C1-6 alkyloxy C1-6alkyl; C1-6 alkylcarbonyl; Cl- 6 alkylsulfonyl; C1-6 alkylthio; Cul-6

alkylsulfinyl; C1-6alkylsulfonarnido; alkyloxy-carbonyl;alkylarylsulfonamido;C1-6 C1-6 alkyloxycarbonyl Cl-6alkyl; RbRCN-C (O)- C1-6alkyl; C1-6alkyl;alkanoylamino aroylamino C1-6 alkyl; wherein the C1-6 alkyl moiety is unsubstituted or substituted with 1-3 C1-4alkoxy;ortrifluoromethyl;of:halo; iii) aryl; aryloxy; arylcarbonyl; arylthio; arylsulfonyl; arylsulfinyl; arylsulfonamido; aryloxycarbonyl; wherein the aryl moiety is unsubstituted or substituted with 1-3 ouf-halo; C1 4alkyl; C1-4alkoxy ; or trifluoromethyl; iv)-C (O) NRbRC ;-O-C (O)-NRbRc;-N (Rb)-C (O)-Rc;- NRbRC; Rb-C (O)-N (Rc)- ; where Rb and Rc Rb and Rc are independently H, C1-6 alkyl, aryl, or arylC1-6alkyl ; wherein the alkyl moiety is unsubstituted or substituted with 1-3 of: halo ; C1-4alkoxy ; or trifluoromethyl; and the aryl moiety can be substituted with 1-3 of: halo ; Cl- 4alkyl; C1-4 alkoxy; or trifluoromethyl; and- N (Rb)-C (O)-ORg, wherein Rg is C1 6alkyl or aryl, in which the alkyl moiety is unsubstituted or substituted with 1-3 of: halo ; C1-4alkoxy ; or trifluoromethyl, and the aryl moiety is unsubstituted or substituted with 1-3 of: halo ; C1 4alkyl; C1-4 alkoxy, or trifluoromethyl;- N (Rb)-C (O) NRCRd wherein Rd is selected from H, C1-6 alkyl, and aryl; in which said Cl- 6alkyl and aryl is unsubstituted or substituted as described above in (f) for Rb and Rc; iv) a heterocyclic group, wherein the heterocyclic ring can be fused with a benzo ring, and wherein said heterocyclic ring is unsubstituted or substituted with one to three substituents, as

defined above for i), ii), iii) and iv), excluding iv) a heterocyclic group.

Preferably, Ar is selected from: unsubstituted or mono-or di-substituted phenyl, naphthyl, pyridyl, furyl, pyrrolyl, thienyl, isothiazolyl, imidazolyl, benzimidazolyl, tetrazolyl, pyrazinyl, pyrimidyl, quinolyl, isoquinolyl, benzofuryl, isobenzofuryl, benzothienyl, pyrazolyl, indolyl, isoindolyl, purinyl, carbazolyl, isoxazolyl, thiazolyl, oxazolyl, benzthiazolyl, and benzoxazolyl.

In another embodiment, Ar is selected from: unsubstituted or mono-or di-substituted phenyl, naphthyl, pyridyl, pyrrolyl, pyrazinyl, pyrimidyl, and oxazolyl.

Preferably, the aryl and heteroaryl substituents are selected from: v) halo; cyano; nitro; trihalomethyl; trihalomethoxy; C 6 alkyl; aryl; C1-6 alkylsulfonyl ; Cri-6 alkyl- arylsulfonamino; vi)-NRbRC; Rb-C (O)-N (Re)- ; wherein Rb and Rc are independently H, C1-6 alkyl, aryl, or arylCl-6alkyl; wherein the alkyl moiety is unsubstituted or substituted with 1-3 of: halo ; C1 4alkoxy; or trifluoromethyl; and the aryl moiety is unsubstituted or substituted with 1-3 of: halo ; C1 4alkyl; C1-4 alkoxy; or trifluoromethyl; vii) a heterocyclic group, which is a 5 membered aromatic ring, containing one ring nitrogen atom, or one ring oxygen and one ring nitrogen atom.

The starting material for the process is produced according to the procedures in Miller et al., Tetrahedron Letters 37 (20) 3429-3432 (1996) and those in PCT publication WO 95/32215, and is generally known and available in the art.

Addition of methyl magnesium chloride to the 7-keto-3,16 bis acetate starting material (1) cleaves the 3 and 16 acetates with concurrent addition to the 7-ketone to produce (2). Anhydrous cerium trichloride, in the proper needle form, was added to the Grignard before addition to the 7-ketone and improved the yield of the rection by >15%.

The triol (2) can be carried on to the next step without purification, or it may be isolated.

Oxidation of the triol (2) to the dienedione (3) was carried out under Oppenauer conditions with 2-butanone, aluminum isopropoxide, and triethylamine. Concurrent hydrolysis of the aluminum salts and elimination of the 7-OH occurred upon aging with concentrated HCl.

Butanone dimers can be removed from the rection mixture by a water distillation before carrying on to the next step, or the dienedione (3) may beisolated.

A chemo-and stereoselective reduction of the dienone (3) to the 7-ß methyl enone (4) was achieved under transfer hydrogenation conditions using 10% Pd/C and cyclohexene as the hydrogen donor.

Careful front run of the rection and frequent monitoring ensured little overreduction and a high yield of enone.

The oxidative cleavage of the enone (4) to the seco acid (5) was carried using sodium periodate and catalytic potassium permangante with sodium carbonate.

Introduction of the nitrogen atom into the A ring occurs in refluxing acetic acid with ammonium acetate. BHT was added as a radical inhibitor to prevent decomposition of enelactam ketone (6).

Chemo-and stereoselective reduction of the crude enelactam ketone (6) was carried out with L-Selectride at-5°C. After an oxidative workup to convert the trialkylboron by-products to boric acid, the enelactam alcohol (7) is crystallized from acetonitrile. Running this rection under more dilute conditions and reducing the level of toluene improves yield.

Hydrogenation of the enelactam alcohol (7) is critical because enelactam left behind does not crystallize away from the NH lactam alcohol (8) and impacts on the purity of the final product.

Arylation of the NH lactam alcohol (8) was carried out using potassillm t-butoxide in N-methyl-pyrrolidinone to give (9). The isomeric purity of the fluoro-substituted aryl reagent is of key concern in this rection because both the ortho and meta isomers of the fluorotoluene also react to give the corresponding isomeric products.

Complete iodination in forming (10) is important since the NH lactam alcohol is not easily removed from the iodide or final bulk drug by recrystallization. The level of NH lactam alcohol in the iodide is typically controlled at less than 0.2wt%. Care must be taken to carry out the quench at low temperature (less than 5°C) in order to avoid reduction of the iodide to the starting material.

Formation of the 1,2-double bond by dehydroiodination forms the product (11).

Representative experimental procedures utilizing the novel process are detailed below. These procedures are exemplary only and should not be construed as being limitations on the novel process of this invention.

Abbreviations : ACN is acetonitrile; BHT is 2,6-t-butyl-4- methylphenol; ca is ;circa DBU is (1,8-diazabicyclo [5.4.0] undec-7-ene; IPA is isopropyl alcohol; L-SelectrideOO is lithium tri-sec- butylborohydride; MEK is methyl ethyl ketone; NMP is 1-methyl-2- pyrrolidinone; THF is tetrahydrofuran; TMEDA is N, N, N', N'- Tetramethylethylenediamine; TMSCl is chlorotrimethylsilane.

EXAMPLE 1 Preparation of 3, 6, 16-Triol (2) Cerium chloride (3.96kg) was charged as a solid to the rection vessel. THF (35kg) was charged using vacuum, then water (20mL) was added via the charge port and the mixture aged at 36°C for 1 hr. A sample was taken and examine by microscopy to ensure that conversion to the required crystal form had occurred.

(Amorphous cerium chloride stirred in THF converts to a fine rod-like crystalline form. This crystalline form is necessary to

obtain the stereo-selectivity in the Grignard rection. Previous experience had shown that the water content of the THF/cerium chloride should be less than 1000ppm in order to get the required crystal form.

Wetter slurries were found to irreversibly form another crystal form that did not exhibit the same specificity in the Grignard rection. However, the THF used in this instance was extremely dry (<50ppm) and stirring the amorphous cerium chloride in it did not produce the required conversion and the solid remained amorphous. It was demonstrated that a small amount of water is necessary for the conversion to take place, and water was added to the batch to give a total water content of ca 500ppm.) After cooling the batch to 25°C, 3M methyl magnesium chloride in THF (80.46kg) was added to the vessel. The mixture was cooled to 0-5°C and aged for 30 minutes. The 7-ketone starting material (1) (9.2 kg) was slurried in THF (50L) and added to the Grignard reagent slurry over 75 minutes, maintaining a temperature of <20°C.

The batch was sampled and rection completion confirme by HPLC: <O. lA% (1) detected. The Grignard rection mixture was slowly added to a quenching solution formed by the addition of toluene (70 kg) to a solution of water (146L) and solid citric acid (43.9kg). Care was made to maintain the temperature at <20°C. The rection vessel and transfer lines were rinsed with THF (lOkg).

The mixture was stirred for 15 minutes then settled for 30 minutes. Both phases were cut to drums and the aqueous layer returned to was back extracted with 39 kg of ethyl acetate (agitated for 10 mins, settled for 30 mins). The aqueous layer was cut to waste drums and the THF batch layer was combine with the ethyl acetate layer. 20% sodium carbonate solution (49.2kg) was added to the stirred solution over 15 minutes then the mixture settled for 30 minutes and the aqueous phase cut to waste.

The batch layer was washed with 51.5kg of 20% sodium chloride solution (agitated for 10 mins, settled for 30 minutes) and the aqueous phase cut to waste. Triethylamine (4.8kg) was added and the solution concentrated in vacuo to ca 100L. Toluene was added and distillation continued, until the level of THF/ethyl acetate had dropped to

<0. 5vol% by GC. The final volume was made up to 275L, with toluene and the slurry held was used in Example 2.

HPLC Conditions: Column YMC J-Sphere ODS H80 250 x 4.6 mm I. D.

Eluent A ACN Eluent B Unbuffered water Gradient 30% A to 80% A in 25 min; hold for 5 min Inj vol 20 µl Detection W at 200nm Flow 1.5 ml/min 35°CColumntemp Sample preparation 100x dilution with acetonitrile; waste aq layers diluted 50x Compound Retention Times Response Factor (area counts/wt) Triols 4.6,6.4 0.71 7-ketone 14.6 1 Toluene 16.4 BHT 29.5 GC conditions Column Chrompack plot fused silica 25mx0.53mm coating poraplot la Oven temperature 250°C Isothermal Inj temp 275°C Det temp 275°C Sample preparation 40x dilution with MeOH Compound Retentis Relative Res,onseFator MeOH 2.0 min THF/EtOAc 2.8,3.2 min 1 Toluene 4.5 min 1.5 EXAMPLE 2 Preparation of Diene-Dione (3) .. Il OH , AI (O-iPr) 3 op 0 3 Toluene, Et3N jp HO CH3 O (2) (3)

To a slurry of thiol in toluene (7.59 kg in 275L) was added triethylamine (3.8kg) and aluminium isopropoxide (10kg) followed by 2- butanone (100kg). The mixture was heated at reflux for 6 hrs, cooled slightly, a sample was taken, and rection completion confirme by HPLC (<5A% 16-OH's dienone relative to 16-keto-diene-dione). The batch was cooled to 20°C, then allowed to stand overnight.

A mixture of water (62.5L) and 12N hydrochloric acid (73.7kg) was transferred to the rection mixture. The rection mixture was heated to 58-60°C and aged for 4 hrs. A sample was taken and the disappearance of 7-OH enone intermediate confirme by HPLC. The batch was cooled to 20°C, allowed to settle for 15 mins and the aqueous phase cut to waste.

2.5% sodium bicarbonate solution (100L) was added to the toluene layer, stirred for 15 mins, settled for 30 mins and the aqueous phase cut to waste. This procedure was repeated with 100L of water.

The organic phases from the two batches prepared as described above were combine and concentrated in vacuo to a volume of 100L. Water was fed in under vacuum then distillation continue at atmospheric pressure until the level of 2-butanone dimers in the batch had dropped to <3A% relative to diene-dione; a total of 70L of water was distille. Toluene (100L) was added to the residue, the mixture agitated for 5 mins then settled for 15 mins. The organic layer was saved. The aqueous phase returned was extracted with toluene (40L). The organic

layers were combine and concentrated in vacuo to a final volume of ca 60L. The solution was held for Example 3.

HPLC Conditions Column YMC J-Sphere ODS H80 250 x 4.6 mm I. D.

Eluent A ACN Eluent B Unbuffered water Gradient 30% A to 80% A in 25 min; hold for 5 min Flow 1.5 ml/min Inj vol 20 µl Detection UV at 200nm for triols, 240nm for 7-OH enone and MEK by-product removal, 290 nm for dienone assays Column temp 35°C Sample preparation 100x dilution with acetonitrile; waste aq layers diluted25-50x Compound Retention Times l Triols 4.6,6.4 200nm 7-OH enone 6.6 240nm Dienedione 13.1 290nm Toluene 16.4 200nm BHT 29.5 200nm EXAMPLE 3 Presaration of Enone (4) 10% Pd/C, O EtOH, Toluene, DBU 3) O Diene-dione (3) (12.9 kg) was converted to enone (4) (11.69 assay kg, 90.0% yield) in one batch. The enone was not isolated but carried through for use in Example 4 as a solution in t-butanol.

To the rection vessel was added 10% Pd/C (5.32kg, 51.5% water wet), followed by the toluene solution of diene-dione obtained as a product of Example 2, (12.9kg in 70L), ethanol (38.1L), and cyclohexene (64.9L). The mixture was agitated and DBU (1.28kg) was added.

A sample was taken and the mixture warmed to reflux.

The rection was sampled periodically and heating continued (6 hrs) until the diene-dione level, measured by HPLC fell below 1. 0mg/ml.

(As benzene is produced as a by-product of the rection, care was taken to use local extraction when sampling.) After cooling to 25°C, the batch was filtered through a 45cm plate filter set with a polypropylene cloth, card, and Solka Floc diatomaceous earth (1.5kg).

The filter became blocked after about 50% of the slurry had passed through and had to be dismantled and reset.

The vessel, lines and filter pad were rinsed with toluene (20L) and the combine filtrates allowed to stand overnight. 1N hydrochloric acid (44L) was added to the filtrate. The mixture was agitated for 5 mins, settled for 15 mins and the lower aqueous phase cut to waste. This wash procedure was repeated with 5% sodium chloride solution (42L).

The organic phase was concentrated in vacuo to ca 50L then transferred to a rection vessel via a 0.5m cotton cartridge filter and distillation continued to ca 22L. The solvent was switched to t-butanol. t- Butanol (total of 144kg) was charged and distille in vacuo (30L distille) until the required removal of the previous solvents was achieved (toluene <15mg/ml, cyclohexene, 0.05mg/ml). The batch (11.69kg of enone in 136.2kg of solution) was held for further rection in Example 4.

(Because t-Butanol freezes at 26°C, all drums of pure solvent and batch solutions were stored on a heating pad to maintain a temperature of ca 40°C.) HPLC Conditions Column Zorbax SB Phenyl 250 x 4.6 mm I. D.

Eluent A ACN Eluent B Aqueous O. lv/v% H3P04 Gradient 30% A to 80% A in 25 min; hold for 5 min

Flow 1.5 ml/min Inj vol 20 µl Detection W at 192nm (benzene, cyclohexene), 245nm (none), 295nm (dienone) Column temp 35°C Sample preparation 100x-1000x dilution with acetonitrile; waste aq layers diluted lOx-25x (non-linearity for dienedione, enone) Compound Retention Times Benzene 7.7 Toluene 10.0 Cyclohexene 10.9 Dienedione 13.9 Enone 14.9 EXAMPLE 4 Preparation of Seco acid (5) O H 02C O KMn04 O NalO4/t-BuOH/H20 0 (4) (5) Enone (4) (11.69 assay kg) was converted to seco acid (10.3 assay kg) in 83% yield in two batches. The product was not isolated but held as a solution in ethyl acetate for Example 5.

The oxidizing solution was made up first. Water (150L), sodium periodate (25.54kg) and potassium permanganate (0.47kg) were added to the rection vessel and the mixture warmed to 65°C until all the solids had dissolve (ca 30 minutes).

A solution of enone (4) (5.9 kg) in t-butanol (70 kg) was added to a second rection vessel and rinsed in with t-butanol (16 kg). A

solution of sodium carbonate (2.10 kg) in water (80 L) was added to the enone solution and stirred at 55°C. The oxidant was added over 1 hr, maintaining the temperature at 60°C.

The batch was aged at 60°C for 30 mins then sampled and assayed for starting material (0.07mg/ml, 99% complet), and then heated at 80°C for 30 mins to decompose excess oxidant. The resulting brown slurry was cooled to 12-15°C, aged for 15 mins then filtered through a 65cm filter fitted with a polypropylene cloth. The vessel and filter pad were rinsed with aqueous t-butanol (water 70L, t-butanol 35L).

The filter removed the bulk of the inorganic solids but some fine brown material passed through.

The liquors were returned to the rection vessel via a 0.5m cotton cartridge filter, then the pH of the solution was measured at 9.

The cartridge filter became blocked with the fine brown inorganic solid and required changing several times dring the transfer. If the pH had been <9, it would have been adjusted by addition of sodium carbonate solution.

Hexane (30kg) was added. The mixture was agitated for 15 minutes, settled for 15 mins then the aqueous layer cut to drums and the hexane layer cut to waste. The aqueous phase was returned to the rection vessel together with ethyl acetate (41kg), then the pH of the batch adjusted to 1-2 by addition of 12N hydrochloric acid solution, maintaining the temperature at 15-20°C. The mixture was stirred for 15 mins, settled for 30 mins and both phases cut to plastic lined drums.

The aqueous phase was returned to the vessel and extracted with ethyl acetate (26kg). This extraction was repeated, and then all the organic phases combine in the rection vessel, and washed with 10% brine solution (27L). The aqueous phase was cut to waste and the organic phase drummed and assayed.

HPLC Conditions Column Zorbax SB Phenyl 250 x 4.6 mm I. D.

Eluent A ACN Eluent B Aqueous 0. 1v/v% H3P04 Gradient 30% A to 80% A in 25 min; hold for 7 min Flow 1.5 ml/min

Inj vol 20 W Detection W at 192nm (seco acid), 245nm (enone) Column temp 35°C Sample preparation 100x dilution with acetonitrile; waste aq, hexane layers diluted lOx-25x Compound Retention Times Acetic acid 2.1 Ethyl acetate 3.6 Seco acid 8.1 Toluene 10.0 Enone 14.9 EXAMPLE 5 Preparation of Enelactam Ketone (6) Seco-acid (9.8kg) was converted to ene lactam ketone (9.07kg) in a single batch. The product was not isolated, but instead carried through to Example 6 as a toluene solution.

A solution of seco-acid (10.3kg) in ethyl acetate (282kg) was added to a rection vessel and concentrated in vacuo to a minimum stirred volume of ca 35L. The solvent was then switched to acetic acid in vacuo. A total of 80kg of acetic acid was added, and 60L distille to achieve an ethyl acetate concentration of <lmg/ml in a final volume of 76L (seco-acid concentration: 124.9g/L). A portion of this solution (4L, containing 500g of seco-acid) was removed for other studies.

The remaining solution (9.8kg in 72L) was diluted with acetic acid to a total volume of 150L, then BHT (O. lkg) and ammonium acetate (23.7kg) were added via the charge port and the mixture warmed to reflux. Acetic acid (60L) was distille and then reflux continued for a total of 5 hrs. The progress of the rection was monitored by HPLC and the rection was considered complete when the concentration of seco- acid fell to <0.5mg/ml.

The batch was cooled to 20°C, then toluene (100L) and water (100L) added, the solution stirred for 20 mins, settled for 20 mins and both phases cut to plastic lined drums. The aqueous phase was returned to the rection vessel and extracted with toluene (50L). The organic phases were combine, washed with 5% aqueous sodium chloride solution (50L) and assayed (total volume 160L, 56.7g/L for 98.5% yield).

The solution was concentrated in vacuo to give a thick slurry (37L) of ene-lactam ketone.

HPLC Conditions Column Zorbax SB Phenyl 250 x 4.6 mm I. D.

Eluent A ACN Eluent B Aqueous 0.1v/v% H3PO4 Gradient 30% A to 80% A in 20 min; hold for 15 min Flow 1.5 ml/min Inj vol 20 p1 Detection W at 192nm (seco acid), 240nm (enelactam) 35°CColumntemp Sample preparation 100x dilution with acetonitrile; waste aq layers diluted25x Compound Retention Times Acetic acid 2.1 Ethyl acetate 3.5 Seco acid 8.5 Toluene 9.4 Enelactam ketone 9.9 BHT 17.1

EXAMPLE 6 Preparation of Enelactam Alcohol (7) 1. L-Selectride +/-5° C, THF OH 2. H202, NaOH H O, N The slurry of ene-lactam ketone (9.07kg) in toluene (35L) in the rection vessel was diluted with THF (89kg) and cooled to-5°C. L- Selectride (34.5kg of 1M solution) was added to the slurry over 1 hr, maintaining the temperature between-5°C and 0°C. The batch was aged at 0°C for 20 mins then sampled. HPLC analysis showed that 11.7 mol% still remained. Further L-Selectride (3.4kg) was added then aged for 40 minutes at 0°C and sampled. HPLC analysis showed that 9.9 mol% still remained.

The rection was quenched by addition of 20% aqueous sodium hydroxide solution (37.4kg), maintaining the temperature at <20°C, followed by 27% hydrogen peroxide (19.8kg) at <30°C. The mixture was stirred at 15-20°C for 1 hr then excess peroxide confirme using a Merckoquant test strip (E. Merck).

The nitrogen purge rate was increased to 15min during the hydrogen peroxyde addition.

10% aqueous sodium sulfite solution (129kg) was added, and the batch aged for 15 mins. The absence of peroxide was confirme, and then the batch was settled for 15 mins and the aqueous phase cut to waste. 10% aqueous sodium chloride solution (58kg) was added, the mixture agitated for 5 mins, settled for 15 mins and the aqueous phase cut to waste. The brine wash was repeated.

The organic phase (128.3kg) was transferred to another rection vessel via a 0.5m cotton cartridge filter. The batch was concentrated to ca 40L at atmospheric pressure then the solvent was switched to acetonitrile. A total of 200kg of acetonitrile was charged and

the mixture distille to a final volume of 65L. A sample was taken and toluene level (spec-200mg/ml, measured-0.7mg/ml) and KF (spec- 400mg/L, measured-73mg/k) measured.

The batch was allowed to cool to room temperature slowly overnight with gentle agitation, and then cooled to 5°C over 1 hr and aged for 30 minutes. The solid was collecte on a 33cm stainless steel filter, washed with acetonitrile, then dried at ambient temperature in vacuo overnight. The dry solid was bagged.

HPLC Conditions: Column Zorbax SB Phenyl 250 x 4.6 mm I. D.

Eluent A ACN Eluent B Aqueous 0.1v/v% H3PO4 Gradient 30% A to 80% A in 20 min; hold for 15 min Flow 1.5 ml/min Inj vol 20, ul Detection W at 240nm (enelactam ketone, enelactam alcool) and 200nm (BHT, toluene) Column temp 35°C Sample preparation 100x dilution with acetonitrile; waste aq layers, filtrate and washes diluted 25x Compound Retention Times Enelactam 16-ß alcohol 8.7 Toluene 9.5 Enelactam ketone 9.9 BHT 17.1 EXAMPLE 7 Preparation of Lactam Alcohol (8)

Ene-lactam alcohol (750g) was dissolve in a mixture of IPA (10L) and water (1.6L) by warming to 30-40°C in a 20L flask. BHT (3g) and 50% wet 10% Pd/C (375g) was added and the mixture charged using vacuum via the dip-leg to a 20L autoclave, and then rinsed in with IPA (1L). The slurry was stirred under an atmosphere of hydrogen (60psi) at 50°C for 6 hours then at 68°C for 16 hrs. The batch was sampled via the dip-leg and checked for completion by HPLC (spec<0.05A% starting material). If the end point had not been reached, stirring under hydrogen was continue.

The hydrogenation was carried out at 50°C for the first few half-lives and then warmed to 68°C. Meeting the end of rection specification is important as ene-lactam alcohol is carried through to the final product.

The batch was cooled to 30-40°C, flushed with nitrogen several times, then transferred from the autoclave and filtered through Solka Floc (lkg). The autoclave and filter pad were washed with 1: 10 water/IPA (2L), and the combine filtrates stored.

The procedure above was repeated 10 times and the 10 batches of filtrate were combine and concentrated at atmospheric pressure to a volume of ca 25L. After cooling to room temperature, water (42L) was added over 45 minutes and the batch cooled to 5°C and aged for 1 hr. The solid was collecte on a 33cm filter fitted with a polypropylene cloth and then washed with 4: 1 water/IPA (1OL). The damp solid was transferred to trays and dried in vacuo at 35°C overnight to give the lactam alcohol (8).

EXAMPLE 8 Preparation of Aryl-NH-Lactam (9)

O H 1 KOtBu, NMP, 4\ 4-fluorotoluene 140°C H H'Me (8) (9) To the lactam-alcohol (8) (3.1 kg) in NMP (46.5 L) at 20°C was added KOtBu (4.74 Kg). The mixture was aged at 20°C for 20 min. 4- Fluorotoluene (2.21 Kg) was added in one portion. The slurry was heated to 140°C until less than 0.5A% starting material remained by HPLC analysis.

Sample preparation, 100µl diluted to 10mol with ACN HPLC Conditions: Column YMC JSphere ODS 80H 4.6mm x 25cm Eluent A CH3CN Eluent B Aqueous O. 1M H3P04 Gradient 50% A ramp to 80% A over 7 in hold for 33 min.

Flow rate 1.2ml/min~ Inj vol 201l1 Detection UV at 200nom.

Temp 20°C Retention times: NH Lactam 3.3 min Fluorotoluene 9.2 min ANHL 22.1 in

Ortho isomer 24.2 min Meta isomer 21.4 min 16-Alpha isomer 19.0 min 5-Beta isomer The rection mixture was cooled to 20°C and water (46.5L) was added over lh maintaining temperature 20-30°C. The slurry was stirred at 1h.20°Cfor The slurry was filtered, washed with water (10 L) and dried using nitrogen stream overnight.

EXAMPLE 9 Preparation of Aryl-NH-Iodo-Lactam (10) To a solution of arylated NH lactam (9) (3.3 Kg) in THF (66 L) at-5°C was added TMEDA (3.76 L) and TMSCl (2.64 L). The white slurry was stirred at-5°C for 15 minutes. Iodine (4.24 Kg) was added to the slurry in three portions over 20 min.

HPLC Conditions for Rection: Column Zorbax SB Phenyl 4.6mm x 25cm Eluent A CH3CN Eluent B Aqueous O. lM H3PO4 Isocratic 70% A, 30% B Inj vol 20µl Detection W at 200nm.

Temp 20°C Retention times: Iodolactam 8.2 Arylated NHL 10.5

The rection mixture was stirred at 0°C for 3h until lactam SM was less than 0.1A% vs product (200nu). The rection mixture was cooled to-10°C and a cold (5°C) freshly prepared solution of sodium sulfite in water (1.65 Kg in 33 L) was added to the rection mixture over 20 min maintaining the quench temperature <5°C.

A color change to pale yellow from dark brown was observe.

The mixture was seeded with iodide (10 gm) and water (66 L) added over lh at 5°C. The resultant slurry was aged at 5°C for lh.

The slurry was filtered, washed with water (33 L) and dried in a nitrogen stream on the filter funnel overnight to yield pure (10).

EXAMPLE 10 Preparation of 4-aza-7ß-methyl-16ß-(4-methylphenoxy)-5α-androst-1-en- 3-one(11) Me Me / zo zo ''-/ p H 1. KOtBu, THF O H H DMF,-15°C (10) 2. Water (11) To a solution of potassium t-butoxide (6.8 Kg) in dry DMF (19.8 L) at -15°C under a nitrogen atmosphere was added a slurry of iodo- lactam (3.95 Kg) in dry THF (19.8 L) over approx lh. THF (1 L) was used as vessel and line rinse. The rection temperature was maintained <-15 to-10°C during addition.

Cafter a 15 min age a sample was taken for analysis by HPLC.

HPLC Conditions: Column Zorbax SB Phenyl 4.6mm x 25cm

Eluent A CH3CN Eluent B Aqueous 0.1M H3PO4 Isocratic 70% A, 30% B Inj vol 20R1 Detection LTV at 200nm.

Temp 20°C Retention times: Iodolactam 8.2 (11) 8.9 Arylated NHL 10.2 Water (45 L) was added over 20 min maintaining the temperature <10°C. The resultant slurry was aged at 5°C for 2h. The slurry was filtered and washed with water (15 L). The cake was dried in air to <15wt% water.

The wet cake was dissolve in THF (30 L) at room temperature and filtered through a 5 micron in-line filter into a 50L vessel. The glassware and line were washed with THF (1 L). The filtrates were concentrated at reduced pressure to about 10L. N-Butyl acetate (20L) was added and concentration continue at atmospheric pressure to a final volume of about 10L.

The hot (120°C) solution was cooled to 80°C and seeded with product (11) (2 gm). The resultant slurry was aged at 80°C for 30 min then cooled to-5°C over 2h.

The slurry was filtered and the cake washed with cold n- butyl acetate (1 L) and dried in a nitrogen stream overnight.

EXAMPLE 11 According to the procedures outlined in Examples 1-10, the following compound of structural formula below are prepared

Compound Ar 12 phenyl 13 4-chlorophenyl While the foregoing specification teaches the principles of the present invention, with examples provided for the purpose of illustration, it will be understood that the practice of the invention encompasses all of the usual variations, adaptations, and modifications, as come within the scope of the following claims and its equivalents.